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Studies of the bioavailability of proanthocyanidins usually consider them independently 39 
of other dietary constituents, while there is a tendency in the field of functional foods 40 
towards the combination of different bioactive compounds in a single product. This 41 
study examined the long-term effects of ω-3 polyunsaturated fatty acids of marine 42 
origin on the metabolic fate of grape proanthocyanidins. For this, female adult Wistar-43 
Kyoto rats were fed (18 weeks) with a standard diet supplemented or not with 44 
eicosapentaenoic acid/docosahexanoic acid (1:1, 16.6 g/kg feed), proanthocyanidin-rich 45 
grape seed extract (0.8 g/kg feed) or both. A total of 39 microbial-derived metabolites 46 
and 16 conjugated metabolites were detected by HPLC-MS/MS either in urine or in the 47 
aqueous fraction of feces. An unexpected significant increase in many proanthocyanidin 48 
metabolites in urine and feces was observed in the group supplemented with ω-3 49 
polyunsaturated fatty acids group as compared to the animals fed a standard diet, which 50 
contains a small amount of polyphenols. However, proanthocyanidin metabolites in rats 51 
given ω-3 polyunsaturated fatty acids and grape seed extract did not significantly differ 52 
from those in the group supplemented only with grape seed extract. It was concluded 53 
that ω-3 polyunsaturated fatty acids collaborate in the metabolism of polyphenols when 54 
present at low doses, while the capacity of ω-3 polyunsaturated fatty acids to induce 55 
microbiota transformations when proanthocyanidins are present at high doses is not 56 





1. INTRODUCTION 61 
Polyphenols are a large group of compounds found in plant foods that have been shown to 62 
have health-related effects in relation to several chronic diseases (Scalbert et al., 2005). 63 
Flavanols, included in the family of flavonoids, are among the most studied polyphenols. 64 
They range in complexity from monomers, such as (+)-catechin or (‒)-epicatechin, to 65 
combinations of these structures via different linkages, which gives rise to the 66 
corresponding oligomers or polymers- (proanthocyanidins, PAs). Flavanols are found in 67 
many common foods, such as grapes, nuts or cocoa, and have been shown to have 68 
beneficial effects in relation to different markers of cardiovascular disease. Indeed, the 69 
European Food Safety Agency approved a health claim regarding the effects of cocoa 70 
flavanols on endothelium-dependent vasodilatation (EFSA, 2006). 71 
A key aspect of the study of PAs is the proper knowledge of their metabolic fate, since they 72 
are extensively transformed after ingestion. Dimers and to a lesser extent trimers may be 73 
absorbed in the small intestine; the former may be methylated while no post-absorption 74 
transformation has been reported for trimers (Monagas et al., 2010). However, most 75 
ingested PAs reach the colon, being either extensively depolymerized and absorbed as 76 
monomers or metabolized by the gut microbiota (Touriño et al., 2011). Monomers are 77 
extensively conjugated in the liver and then circulate in the body before being excreted in 78 
urine or accumulated in tissues, or they return to the intestine via enterohepatic circulation. 79 
While for those PA transformed by the microbiota, the resulting metabolites are mostly 80 
phenolic acids that may be absorbed and follow the same routes as polyphenols absorbed 81 
in the small intestine (Urpí-Sardá et al., 2009; Monagas et al., 2010; Mateos-Martín, Pérez-82 
Jiménez, Fuguet, & Torres, 2012a). Increasing evidence suggests that circulating 83 
polyphenol-derived metabolites, especially those produced during colonic fermentation, 84 
may be the compounds responsible for the health-related properties of these food 85 
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constituents (Williamson, & Clifford, 2010). 86 
To elucidate the metabolic fate of polyphenols, they are administered alone and in acute 87 
doses (Urpí-Sardá et al., 2009; Monagas et al., 2010; Touriño et al., 2011; Mateos-Martín 88 
et al., 2012a). In a common diet, however, polyphenols are consumed in combination with 89 
other food components, which may have either synergic or antagonistic effects on their 90 
bioavailability. Moreover, there is currently increasing interest in the development of 91 
functional foods with combinations of bioactive components (Peluso, Romanelli, & 92 
Palmery, 2014), which may affect the bioavailability of polyphenols and the health effects 93 
derived from them. Therefore, now that the general process of transformation of these 94 
compounds has been reported, there is increasing interest in the effects that other food 95 
constituents, such as carbohydrates, proteins or dietary fiber, may have on their 96 
bioavailability (Bohn, 2004; Zhang et al., 2014).    97 
In relation to dietary fat, studies with animal models (Lesser, Cermak, & Wollfram, 2008) 98 
and humans (Tulipani et al., 2002; Guo et al., 2013) have reported that this food constituent 99 
increases the bioaccessibility and absorption of certain flavonoids, through different 100 
mechanisms. Differential effects of long-chain and medium-chain fatty acids on the 101 
bioavailability of polyphenols are probably due to the different metabolic routes that these 102 
compounds follow (Lesser, Cermak, & Wollfram, 2006; Murota, Cermak, Terao, & 103 
Wollfram, 2013). In contrast, the effects of fatty acids with different degree of unsaturation 104 
on the metabolic fate of polyphenols have not been explored. Indeed, studies in this area 105 
have only evaluated the differential effects of saturated and monounsaturated fats (Tulipani 106 
et al., 2002; Lesser, Cermak, & Wollfram, 2006; Lesser, Cermak, & Wollfram, 2008; Guo 107 
et al., 2013; Murota et al., 2013), and to the best of our knowledge, only one in vitro study 108 
has considered the effects of a polyunsaturated fat: hazelnut oil (Ortega, Macià, Romero, 109 
Reguant, & Motilva, 2011). 110 
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Long-chain ω-3 PUFAs of marine origin are a class of bioactive dietary components that 111 
have generated a great deal of interest due to their beneficial effects in both animal and 112 
human studies, on parameters related to cardiovascular disease (Aguilera, Díaz, Barcelata, 113 
Guerrero, & Ros, 2004; Lorente-Cebrián, Costa, Navas-Carretero, Zabala, Martínez, & 114 
Moreno-Aliaga, 2013). In a common diet, and in supplements containing different 115 
bioactive compounds, polyphenols may be consumed together with ω-3 PUFAs and 116 
different interactions may take place (Peluso et al., 2014), which could also affect their 117 
metabolic fate. Therefore, the aim of this study was to evaluate the effect that ω-3 PUFAs 118 
had on the metabolic fate of grape PAs after long-term in vivo supplementation. To this 119 
end, a pilot study was carried out in Wistar-Kyoto rats, and the profile of polyphenol 120 
metabolites was measured by targeted HPLC-ESI-MS/MS analysis of urine and the 121 
aqueous fraction of feces. 122 
2. MATERIALS AND METHODS 123 
2.1 Chemicals and reagents  124 
The standard diet was Teklad Global 2014 (Harlan Teklad Inc., Indianapolis, IN, USA). 125 
Fine Grajfnol® powder, 98% grape seed, was obtained from JF-Natural Product (Tianjin, 126 
China), with the following composition: total PAs (UV), ≥ 95%; oligomeric PAs, ≥ 60%; 127 
procyanidin dimer B2 (HPLC), ≥ 1.8%; ash,  1.5%; weight loss on drying,  5.0%. 128 
Porcine gelatin type A 240/260 was from Juncà (Girona, Spain) and the soybean lecithin 129 
Topcithin 50 from Cargill (Barcelona, Spain). Oil with an eicosapentaenoic 130 
acid:docosahexanoic acid (EPA:DHA) ratio of 1:1 was obtained by mixing appropriate 131 
quantities of the commercial fish oils AFAMPES 121 EPA (A.F.A.M.S.A., Vigo, Spain), 132 
EnerZona Omega 3 RX (Milan, Italy) and Oligen liquid DHA 80% (IFIGEN-EQUIP 98, 133 
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S.L., Barcelona). Soybean oil, obtained from unrefined organic soybean oil (first cold 134 
pressing), was from Clearspring Ltd. (London, UK).   135 
Ketamine chlorhydrate was purchased from Merial Laboratorios (Barcelona, Spain) and 136 
xylazine from Química Farmaceutica (Barcelona, Spain). Standards of (‒)-epicatechin (≥ 137 
98%), (‒)-epigallocatechin (≥ 95%), 3-hydroxyphenylacetic acid (≥ 99%), 4-138 
hydroxyphenylacetic acid (≥ 98%), 3,4-dihydroxyphenylacetic acid (≥ 98%), 3- 139 
hydroxybenzoic acid (≥ 99%), 4-hydroxybenzoic acid (≥ 99%), homovanillic acid (≥ 140 
98%), vanillic acid (≥ 97%), caffeic acid (≥ 98%), 3,4-dihydroxyphenylpropionic acid (≥ 141 
98%), 3-hydroxyphenylpropionic acid (≥ 98%), 4-hydroxyphenylpropionic acid (≥ 98%), 142 
3,4-dihydroxybenzoic acid (≥ 97%), benzoic acid (≥ 99%), hippuric acid (≥ 98%), ferulic 143 
acid (≥ 99%), isoferulic acid (≥ 97%), p-coumaric acid (≥ 98%), m-coumaric acid (≥ 98%), 144 
gallic acid (≥ 97%), enterodiol (≥ 95%), phenylacetic acid (≥ 99%), taxifolin (≥ 85%), and 145 
tert-butylhydroquinone and formic acid (analytical grade) were obtained from Sigma 146 
Chemical (St Louis, MO, USA). Methanol (analytical grade) and hydrochloric acid (≥ 147 
85%) were from Panreac (Castellar del Vallès, Barcelona, Spain). Acetonitrile (HPLC 148 
grade) was obtained from Merck (Darmstadt, Germany). Water for the assay solutions was 149 
obtained using a water Milli-Q purification system (Millipore Corporation, Billerica, MA, 150 
USA). 151 
2.2 Diets 152 
Four diets were prepared: the standard diet; the standard diet supplemented with ω-3 153 
PUFAs; the standard diet supplemented with grape seed extract; and the standard diet 154 
supplemented with both ω-3 PUFAs and grape seed extract. The diets without ω-3 PUFAs 155 
were enriched with soybean oil in order to make them isocaloric. All the diets were 156 
prepared in-house and included tert-butylhydroquinone as an antioxidant, porcine gelatin 157 
to promote gelatinization and soybean lecithin as an emulsifier. The mixtures were freeze-158 
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dried to obtain pellets that were stored at 4ºC to prevent oxidation and fungal 159 
contamination. The composition of each diet, including the supplementations with ω-3 160 
PUFAs and GSE, as well as both the macronutrient and micronutrient profile, is shown in 161 
Supplemental Table 1. A mixture of EPA and DHA in a ratio of 1:1 was used, since it has 162 
been suggested that each fatty acid may have different health effects (Lorente-Cebrián et 163 
al.  2013). This ratio was previously reported as the most beneficial for cardiometabolic 164 
risk factors (Lluís et al., 2013; Méndez et al., 2013). The fatty acid composition of the 165 
soybean oil and ω-3 PUFA supplement were ascertained by gas chromatography after 166 
methylation (Lepage, & Roy, 1986) and are provided in Supplemental Table 2. Because 167 
PUFAs are extremely susceptible to oxidation and due to the potential toxic effects of lipid 168 
oxidation byproducts, the lipid oxidation level was checked throughout the dietary 169 
interventional experiment (peroxide values < 5 meq. oxygen per kg of oil).  170 
The doses of ω-3 PUFAs (16.6 g/kg feed) and grape PAs (0.8 g/kg feed) were chosen on 171 
the basis of previous studies where similar doses showed beneficial effects (Masson et al., 172 
2008; Castell-Auví, Cedó, Pallarés, Blay, Pinent, & Ardévol., 2013) and as realistic doses, 173 
i.e., doses which could easily be incorporated into a typicalcommon diet. 174 
2.3 Animals and sample collection 175 
Twenty female, 8- to 9-week-old, Wistar-Kyoto rats (Charles River Laboratories, 176 
Wilmington, MA, USA) were housed in cages (n = 2-3/cage) under controlled conditions 177 
of a 12 h light/12 h dark cycle, temperature of 22ºC ± 2ºC and relative humidity of 50% ± 178 
10%. They had free access to water and pelleted feed (Supplemental Table 1) for 18 179 
weeks after being randomly divided into the four dietary groups: STD group (n = 5), given 180 
the standard diet supplemented with soybean oil; ω-3 group (n = 5), given the standard diet 181 
supplemented with ω-3 PUFAs; GSE group (n = 5), given the standard diet supplemented 182 
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with grape seed extract and soybean oil; and ω-3+GSE group (n = 5), given the standard 183 
diet supplemented with both ω-3 PUFAs and grape seed extract. For urine and feces 184 
collection, the rats were individually placed in metabolic cages and deprived of food for 24 185 
h. At the end of the experiment, the rats were fasted overnight and anesthetized by an 186 
intraperitoneal injection of 80 mg/kg of ketamine (Imalgene 1000, Merial Laboratorios 187 
S.A., Barcelona, Spain) and 10 mg/kg of xylazine (Rompun 2%, Química Farmacéutica 188 
S.A., Barcelona, Spain). Female rats were chosen because they had previously been 189 
demonstrated to be as valid model for studying the metabolic fate of PAs (Mateos-Martín 190 
et al., 2012a; Touriño et al., 2011; Molinar-Toribio et al., in press) 191 
The handling and killing of the animals were in full accordance with the European Union 192 
guidelines on the care and management of laboratory animals, and the pertinent permission 193 
was obtained from the CSIC Subcommittee for Bioethical Issues (ref. AGL2009-12 374-194 
C03-03).  195 
2.4 Sample processing  196 
Urine samples were processed following a previously described solid-phase extraction 197 
(SPE) procedure (Touriño, Fuguet, Vinardell, Cascante, & Torres, 2009) for the extraction 198 
of phenolic metabolites. Briefly, Oasis HLB (60 mg) cartridges from Waters Corporation 199 
(Milford, MA, USA) were activated with 1 mL of methanol and 2 mL of water acidified to 200 
pH 3 with formic acid (acid water). The samples (total volume of collected urine) were 201 
loaded, interfering components were removed with 9 mL of acid water and then the 202 
phenolic compounds were eluted with 1 mL of methanol. Taxifolin (final concentration of 203 
5 mg L-1) was used as internal standard.  204 
Fecal samples collected over 24 h were re-suspended in acid water and homogenized on a 205 
vortex. Then, after adding the internal standard (taxifolin, 5 mg L-1) the mixtures were 206 
centrifuged (10000 g, 10 min at 4ºC) to obtain a supernatant containing the aqueous 207 
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fraction of the feces. This supernatant was freeze-dried and re-suspended in 1 mL of acid 208 
water, homogenized on a vortex, and then subjected to SPE and the work-up process 209 
described for the urine samples. 210 
 211 
2.5 HPLC-ESI-MS/MS analysis of polyphenol metabolites 212 
An Applied Biosystems (PE Sciex, Concord, Ontario, Canada) API 3000 triple quadrupole 213 
mass spectrometer with a TurboIon spray source was used in negative mode to obtain MS 214 
and MS/MS data. HPLC separations were performed on an Agilent 1100 series (Agilent, 215 
Waldbronn, Germany) liquid chromatograph equipped with a Phenomenex (Torrance, CA, 216 
USA) Luna C18 (50 x 2.0 mm i.d.) 3.0 μm particle size column and a Phenomenex 217 
Securityguard C18 (4 x 2.0 mm i.d.) column. Gradient elution was performed with a binary 218 
system consisting of [A] 0.1% aqueous formic acid and [B] 0.1% formic acid in CH3CN. 219 
The following increasing linear gradient (v/v) of [B] was used, (t (min), % B): 0,8; 10,23; 220 
15,50; 20,50; 21,100 followed by a re-equilibration step. MS conditions were as previously 221 
described (Touriño et al., 2009). Each metabolite in the urine samples was first identified 222 
by MRM (multiple reaction monitoring) transition of the putative metabolites using a dwell 223 
time of 100 ms and then confirmed either by comparison with a standard when available, 224 
second MRM, or neutral-loss and product ion scan experiments. Identification details are 225 
published elsewhere (Molinar-Toribio et al., in press). The MS conditions for each MRM 226 
transition were optimized by direct injection of metabolite standards, when available; for 227 
other metabolites, the conditions of the most structurally similar standard were used. 228 
Analyst 1.4.2 software from AB Sciex was used for data acquisition and processing. 229 
Standard calibrations curves were made for each metabolite using between 4 and 11 230 
different concentrations for each of them, between 0.001 and 60 mg L-1, and they were 231 
used to determine the concentration of each metabolite in the samples, after correction by 232 
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the internal standard concentration. When no commercial standard was available, the 233 
metabolites were quantified using a structurally related commercial standard. For details of 234 
the calibration curves used, see Supplemental Table 3. The structurally related 235 
commercial standard may still show a different response from that of the metabolite, so this 236 
method should be used mainly for comparative purposes. 237 
2.6 Statistics 238 
Results are expressed as mean concentrations + standard error of the mean (SEM), 239 
expressed in µmol/L urine or µmol/g dried feces, adjusted in both cases per kg feed/kg 240 
body weight. Mean body weight and feed consumption data per group were used for this 241 
adjustment. Since the data did not follow a normal distribution, the non-parametric 242 
Kruskal-Wallis and Mann-Whitney U tests were applied to analyze the significant 243 
differences (P < 0.05) comparing the four groups to one another. The Kruskal-Wallis test 244 
was applied to determine any significant difference between the treatments and, if any 245 
were detected, the Mann-Whitney U test was used to compare all the different pairs of the 246 
treatments. The SPSS IBM 19 package for Windows was used throughout. 247 
3. RESULTS 248 
3.1 Feed intake 249 
Feed intake was monitored throughout the study. Mean values standardized by rat weight 250 
(g/kg rat/day) were: STD group, 59.4 (SEM 2.6); ω-3 group, 41.4 (SEM 4.5); GSE group, 251 
56.4 (SEM 4.2); ω-3+GSE group, 40.0 (SEM 3.6). The intakes in ω-3 group and in the ω-252 
3+GSE group were significantly lower than in the STD group (P 0.020 and 0.0058, 253 
respectively). The mean values of caloric intake (kcal/100 g rat/day) throughout the study 254 
were: STD group, 184.0 (SEM 38.9); ω-3 group, 128.4 (SEM 44.5); GSE group, 174.8 255 
(SEM 44.5); ω-3+GSE group, 124.9 (SEM 39.7).  Similarly, the energy intakes in ω-3 256 
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groups were significantly lower than in the STD and in the GSE groups. Due to these 257 
differences in the intakes, the results were adjusted per feed intake and body weight. 258 
3.2 Conjugated metabolites of (epi)catechin and (epi)gallocatechin in urine 259 
A total of 39 transitions were searched for in urine, corresponding to mono-, di- and tri-260 
conjugated metabolites of (epi)catechin (EC) and (epi)gallocatechin (EGC) (derived from 261 
the combinations of the methylated or Me, sulfated or Sulf and glucuronidated or Gluc 262 
forms). The fragmentation patterns obtained for the different compounds were compared 263 
with those reported in the literature for PA-derived conjugated metabolites (Urpí-Sardá et 264 
al., 2009; Mateos-Martín et al., 2012a).  265 
A total of 8 transitions were detected in the samples, corresponding to 12 metabolites from 266 
EC and 2 from EGC. Different metabolites may be identified by the same transition, since 267 
a substituent may be attached at different positions of the phenolic structure. This is the 268 
case, for example, of Gluc-EC, for which 5 different positional isomers were separated and 269 
identified by HPLC-MS/MS. The identification spectra for Gluc-EC is shown in 270 
Supplemental Figure 1. Characteristic fragments of this metabolite were detected at m/z 271 
289, indicating the loss of the glucuronide moiety, as well as at m/z 175 and 113, 272 
corresponding to the degradation of this moiety. 273 
The concentrations of the conjugated metabolites detected in urine are provided in Table 1. 274 
For the individual metabolites identified, urine concentrations of Gluc-EC-1, Me-Gluc-EC-275 
1, Me-Gluc-EC-2 and Me-Gluc-EC-3 were significantly increased in both the GSE and ω-276 
3+GSE groups, compared to the STD and ω-3 groups (Me-Gluc-EC-2, Supplemental 277 
Figure 2). Gluc-EC-2 was also significantly increased in the GSE group but not in the ω-278 
3+GSE group, compared to the STD group. In the ω-3 group, the urinary excretion of three 279 
glucuronidated EC forms was significantly higher than in the STD group.  280 
Overall, the levels of conjugated metabolites of the monomers of PAs excreted in urine 281 
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were increased in both the GSE and the ω-3+GSE groups as compared to the STD group.  282 
3.3 Microbial-derived metabolites in urine 283 
We searched for 48 transitions, corresponding to the microbial metabolites formed in the 8 284 
different steps of the microbial fermentation of PAs (valerolactones, lignans, phenylvaleric 285 
acids, phenylpropionic acids, phenylacetic acids, benzoic acids, cinnamic acids and 286 
glycinated benzoic acids) in the samples.  287 
A total of 31 transitions were detected in the samples, corresponding to 39 metabolites, 288 
since it is known that the microbial metabolites of some PAs may present structural 289 
isomers—e.g., 3- or 4-hydroxybenzoic acid—and some of them may later be conjugated at 290 
different positions (Redeuil et al., 2011). For instance, the identification of m-coumaric and 291 
p-coumaric acid was based on standard retention times (Supplemental Figure 3). 292 
Metabolite concentrations are shown in Table 2.  293 
In the GSE group, 24 metabolites occurred at concentrations significantly greater than in 294 
the STD group. In the case of the ω-3+GSE group, this affected 19 metabolites. No 295 
significant differences were observed between the two groups supplemented with GSE. In 296 
the ω-3 group, the concentration of 18 metabolites significantly increased with respect to 297 
the STD group- in most of the cases, the concentrations found in this group were lower 298 
than those found in the GSE and in the ω-3+GSE group.  299 
3.4 Microbial-derived metabolites in feces 300 
None of the EC or EGC conjugated metabolites found in urine were detected in feces. 301 
However, 11 microbial-derived metabolites were identified in the fecal samples (Table 3). 302 
In the GSE and ω-3+GSE groups, 7 metabolites were significantly greater than in the STD 303 
group. 4-Hydroxyphenylpropionic acid was also significantly higher in the ω-3+GSE 304 
group as compared to the STD group. In the ω-3 group, 5 metabolites were at significantly 305 
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greater concentrations than in the STD group. The concentrations in the ω-3 and the ω-306 
3+GSE groups were within the same range for some compounds, while 4-307 
hydroxyphenylpropionic acid showed the highest concentration in the ω-3+GSE group, 308 
and 3-hydroxyphenylpropinic acid, Me-hippuric acid-1 and Me-hippuric acid-2 showed the 309 
highest concentrations in the GSE group, although for Me-hippuric acid-1 the increment 310 
was not statistically significant . 311 
4. DISCUSSION 312 
Here, we carried out a pilot study on the effects of ω-3 PUFAs on the metabolic fate of 313 
PAs; an aspect that had not previously been explored. To mimic a human dietary situation, 314 
this was evaluated in rats after long-term exposure to diets that incorporated both 315 
components. PA-derived conjugated EC and microbially generated metabolites were 316 
measured in urine; the biological fluid considered the most appropriate for evaluating the 317 
bioavailability of polyphenols (Pérez-Jiménez et al., 2010), given the short half-life in 318 
plasma of their metabolites. These metabolites were also measured in fecal water, i.e., the 319 
fraction of the feces closest to the colonic epithelium (Gill et al., 2010) that could 320 
potentially be involved in the reported effects of PAs on colonic health (Rossi, Bossetti, 321 
Negri, Lagiou, & La Vecchia, 2010; Sánchez-Tena et al., 2013). Since intakes were 322 
significantly different between the groups- i-e., the lowest intakes were found in the ω-3 323 
groups- metabolite concentrations were adjusted per feed intake. Nevertheless, metabolite 324 
concentrations in the GSE groups were in the same range as those reported in studies with 325 
similar supplementations for shorter periods (Tsang et al., 2005; Choy et al., 2014). Also, 326 
the nature of the metabolites found was the same as that of those previously reported in 327 
studies of the metabolic fate of PAs, a process described in detail elsewhere (Mosele, 328 
Macià, & Motilva, 2015). This shows that the same tendencies are maintained for long-329 
term supplementation. 330 
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We obtained an unexpected result, in that microbial-derived PA metabolites increased (in 331 
urine and in feces), as did some EC conjugates, in the ω-3 group (without GSE 332 
supplementation). Since these metabolites are not present in the metabolic routes of ω-3 333 
PUFAs, it seems that ω-3 PUFAs collaborated in the transformation of polyphenols already 334 
present in the basic STD diet (and responsible for the values obtained in the STD group). 335 
The STD diet contained wheat middlings, ground wheat and ground corn; cereals that 336 
include PAs among their phenolic compounds (McCallum, & Walker, 1990; Hichem, 337 
Mounir, & Naceur, 2009; Arranz, & Saura-Calixto, 2010). Indeed, the STD diet contains 338 
not only the PAs that occur free in the food matrix (known as extractable PAs), but also the 339 
fraction associated with the dietary matrix, the so-called non-extractable PAs (Arranz, & 340 
Saura-Calixto, 2010) which are also extensively metabolized by the colonic microbiota 341 
after being released from the food matrix (Mateos-Martín, Pérez-Jiménez, Fuguet, & 342 
Torres, 2012b). Our results suggest that ω-3 PUFAs may promote PA metabolism through 343 
interactions with the gut microbiota. This point needs to be addressed further, as the 344 
information available to date is quite limited. It seems that fish oil supplementation 345 
increases the proportion of Lacotobacilliales, as observed in rats with chronic intestinal 346 
rejection (Li, Zhang, Wang, Tang, Zhang, & Li, 2011), in a murine model of colorectal 347 
cancer (Piazzi et al., 2014) and in gnotobiotic piglets, in this last case with an increase in 348 
Lactobacillus paracasei adhesion to the jejunal mucosa (Bomba, Nemcová, Gankarciková, 349 
Herich, Guba, & Mudronová, 2002). In contrast, PUFA supplementation of animal models 350 
resulted in a decrease in Escherichia coli, Bacteroides spp. and Clostidriales spp., among 351 
others (Li et al., 2011; Yu, Zhu, Pan, Shen, Shan, & Das, 2014). Interestingly, 352 
Lactobacillus plantarum has been reported to stimulate the colonic fermentation of red 353 
wine polyphenols (Barroso et al., 2014), which are quite similar to the PAs included in the 354 
GSE tested here. 355 
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In the present study, the STD diet had a soybean oil content similar to that of PUFAs in the 356 
ω-3 diet, in order to make them isocaloric. Since the main constituents of soybean oil are 357 
monounsaturated fatty acids (followed by PUFAs), the changes observed in the microbial 358 
metabolism of PAs also indicate differences in the microbiota profile when consuming 359 
monounsaturated or polyunsaturated fats. Indeed, when comparing the effects on the 360 
human gut microbiome of three kinds of monounsaturated fats with those of two kinds of 361 
polyunsaturated fats, the modifications in the bacteria profile that resulted from the 362 
consumption of  monounsaturated fats were observed to be consistent with those derived 363 
from PUFA consumption (Pu, Khazenehei, Jones, & Khapifaur, 2016).  364 
Additionally, since cereals contain phenolic acids as major phenolic compounds, and these 365 
generate several metabolites in common with those of PAs (Rodríguez-Mateos et al., 366 
2014), it seems plausible that ω-3 PUFAs would also stimulate the release and 367 
transformation of such compounds. Additionally, some metabolites, such as hippuric or 368 
valerolactones, may originate from other food components (Pero, 2010; Molinar-Toribio et 369 
al., in press), so their increase in the ω-3 group might be due to an effect on other 370 
metabolic routes, becoming particularly evident in a long-term study such as this one. 371 
Another interesting result of this study was that, while GSE contained mostly (95%) 372 
oligomeric PAs, in the groups supplemented with it there was an increase in the monomeric 373 
conjugated metabolites of EC. This agrees with our previous suggestion (Pérez-Jiménez et 374 
al., 2010) of a depolymerization of PAs by bacteria, releasing free EC which would then be 375 
subjected to further absorption and conjugation. ω-3 PUFAs also seem to affect the activity 376 
of the bacteria responsible for this, since in the ω-3 groups there was also a tendency 377 
towards an increase in these compounds, as compared to the STD group. 378 
When GSE and ω-3 PUFAs were administered together, the concentrations of the detected 379 
metabolites were in the same range than those found in the GSE group, without significant 380 
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differences. Therefore, ω-3 PUFAs did not have either an enhancing or inhibitory effect on 381 
a diet supplemented with grape PA, despite the enhancing effects they showed towards the 382 
transformation of polyphenols already present in the basal diet. It is known that polyphenol 383 
supplementation causes a shift in microbial communities towards those species indeed able 384 
to transform them, e.g. the Eubacterium rectale group (Selma, Espín, & Tomás-Barberán, 385 
2009; Queipo-Ortuño et al., 2012). We hypothesize that the changes that ω-3 PUFAs may 386 
cause in the microbiota, and that had an effect in the transformation of polyphenols already 387 
present in the basal diet, may not be relevant against the modifications that polyphenols 388 
themselves cause in the microbiota when provided at high doses.  389 
Anyway, the concentration values for the pool of putatively beneficial circulating PA-390 
derived metabolites in the ω-3+GSE group were in the same range than in the GSE group. 391 
So, PA metabolites from GSE are bioavailable for possible collaborative functional effects 392 
with ω-3 PUFAs. Indeed, when evaluating the effects of ω-3 PUFAs and GSE on the 393 
metabolic alterations induced by a high-fat high-sucrose diet, it was observed that the 394 
combination was more efficient than the separate supplements at averting metabolic 395 
alterations (Ramos-Romero et al., 2016).  396 
The main limitations of this study are intrinsic to experiments on the metabolic fate of 397 
polyphenols. First, there is a lack of commercial standards for many metabolites (Kay, 398 
2010), which forced us to express the results as equivalents of the most closely related 399 
compound, with an associated error. Secondly, we had to deal with the high inter-400 
individual variability of results; an aspect widely reported for the metabolic fate of 401 
polyphenols in both animals and humans (Choy et al., 2014; Muñoz-González et al., 2014). 402 
This latter aspect may have been exaggerated in this study, given that it involved long-term 403 
supplementation, where the measured concentrations for each metabolite did not 404 
correspond to the maxima and it is not known when each animal received the last dose of 405 
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polyphenols before fasting, since they were fed ad libitum. Also, more animals would have 406 
increased the statistical power of the test thereby increasing the likelihood of detecting 407 
statistically significant differences in the metabolites. Be that as it may, this did not 408 
preclude us from observing the emergence of some general tendencies, as discussed above; 409 
while at the same time, it has the advantage of reflecting a situation closer to a genuine 410 
human dietary situation. 411 
5. CONCLUSIONS 412 
This study shows that combined long-term supplementation with ω-3 PUFAs and PAs from 413 
GSE to healthy rats did not significantly affect the levels of urinary and fecal PA 414 
metabolites, compared to supplementation with GSE alone. Meanwhile, ω-3 fatty acids 415 
seem to enhance the metabolism of the polyphenols present in the STD feed. ω-3 PUFAs 416 
appear to collaborate in the release and metabolism of polyphenols when they are present 417 
at low doses in the feed matrix, while their capacity to induce transformations when 418 
polyphenols are added at high doses does not seem to be relevant. 419 
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TABLES 
Table 1. (Epi)catechin and (epi)gallocatechin conjugated metabolites in urine from rats fed a standard diet without supplementation (STD) or 
supplemented with ω-3 PUFAs (ω-3), grape seed extract (GSE) or ω-3 PUFAs and grape seed extract (ω-3 + GSE)1. Results expressed as µM, 







ω-3 + GSE 
 
 Mean  SEM Mean  SEM P Mean  SEM P Mean  SEM P 
EC monoconjugated            
Gluc-EC-1 n.d.  n.d.   5.68 2.87 0.0081a, b 
 
6.04 5.21 0.0081a, b 
 
Gluc-EC-2 n.d.  n.d.   3.84 1.93 0.0321a, b 
 
3.29 3.18  
Gluc-EC-3 0.64 0.32 8.00 1.40 0.0081a 
 
3.09 1.21  15.55 5.37 0.0081a 
0.0321b 
Gluc-EC-4 0.32 0.09 2.83 0.75 0.0081a 
 
0.95 0.47  4.49 1.60 0.0081a 
0.0321c 
Gluc-EC-5 0.88 0.44 3.67 0.80 0.0321a 1.96 1.03  6.34 1.86 0.0161a 
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Total 1.84 0.61 14.50 2.86 0.0081a 
 
15.52 6.24 0.0161a 
 
35.72 16.64 0.0081a 
 
EC diconjugated            
Gluc-Sulf-EC 0.97 0.40 1.05 0.20  3.54 1.62 0.0321b 
 
2.99 1.17  
Me-Gluc-EC-1 n.d.  n.d.   0.85 0.28 0.0081a,b 
 
1.39 0.98 0.0081a,b 
 
Me-Gluc-EC-2 n.d.  n.d.   14.79 4.88 0.0081a,b 13.61 9.21 0.0081a,b 
Me-Gluc-EC-3 n.d.  n.d.   5.26 1.68 0.0081a,b 5.79 4.10 0.0081a,b 
Me-Sulf-EC 2.46 0.84 2.00 0.32  3.03 0.58 0.0081a,b 3.85 1.27 0.0161a 
0.0081b 
Total 3.43 1.23 3.05 0.47  27.47 8.09 0.0081a,b 27.64 16.33 0.0161a 
0.0081b 
EC triconjugated            
3Me-EC 1.09 0.27 0.94 0.17  1.07 0.30  1.65 0.48  
2Me-Gluc-EC 0.63 0.23 0.86 0.29  1.51 0.37  1.73 0.75  
Total 1.72 0.47 1.80 0.46  2.58 0.58  3.38 1.17  
 30 
EGC diconjugated            
2Sulf-EGC 14.16 2.81 15.55 2.71  21.69 4.18  27.72 8.75  
EGC triconjugated            
Me-Gluc-Sulf-EGC 3.95 1.23 8.71 1.29  8.17 0.98  16.17 5.95  
n.d., non-detected; Gluc, glucuronide; Me, methyl; Sulf, sulfated  
1 Values are mean + SEM , n=5  
2 Molinar-Toribio et al., in press.      
a differences with respect to STD group; b differences with respect to ω-3 group; c differences with respect to GSE group. Comparisons were performed using the Kruskal-
Wallis and Mann-Whitney U tests; pairs comparisons were performed between all the groups.
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Table 2. Microbial-derived proanthocyanidin metabolites in urine from rats fed a standard diet without supplementation (STD) or supplemented 
with ω-3 PUFAs (ω-3), grape seed extract (GSE) or ω-3 PUFAs and grape seed extract (ω-3 + GSE) 1. Results expressed as µM, adjusted per kg 
feed intake/kg body weight, after quantification with structurally similar commercial standards (see Table S3). 
Metabolite STD2 ω-3 GSE2 ω-3 + GSE 
 Mean SEM Mean SEM P Mean SEM P Mean SEM P 
Valerolactones             
  3- or 4-Hydroxyphenylvalerolactone 24.17 7.33 205.81 15.67 0.0081a 379.24 129.69 0.0081a 604.60 268.55 0.0081a 
  3,4-Dihydroxyphenylvalerolactone 5.97 4.09 89.81 26.91 0.0081a 219.53 73.37 0.0081a 595.09 281.69 0.0081a 
  Gluc-3,4-dihydroxyphenylvalerolactone 51.48 15.61 133.16 41.14  164.87 29.47 0.0081a 318.25 115.12 0.0321a 
  Sulf-3,4-dihydroxyphenylvalerolactone 15.92 9.76 535.46 98.76 0.0081a 1373.86 117.59 0.0081a,b 1638.69 604.44 0.0081a 
  3-Hydroxyphenylmethylvalerolactone 24.17 7.20 32.31 4.5  93.35 26.46 0.0081a 
0.0321b 
56.64 16.46  
  4-Hydroxyphenylmethylvalerolactone 214.92 73.50 341.12 59.26  628.27 174.41 0.0321a 481.06 125.84  
  Gluc-3-hydroxymethylphenylvalerolactone 112.73 42.56 128.90 58.41  171.21 23.38 0.0321b 170.88 57.94  
  Sulf-3- or 4-hydroxymethylphenylvalerolactone 69.40 23.06 37.77 7.81  91.63 16.42  77.34 22.49  
  Total  517.06 103.86 1504.34 305.22 0.0081a 3121.97 446.61 0.0081a 
0.0321b 
3987.54 1393.77 0.0081a 
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Lignans            
  Enterolactone >60  >60   >60   >60   
  Sulf-enterolactone >60  >60   >60   >60   
Phenylvaleric acids            
  3-Hydroxyphenylvaleric acid  31.10 13.42 20.63 5.25  102.08 15.47 0.0161a 
0.0081b 
157.89 73.49 0.0321b 
  4-Hydroxyphenylvaleric acid  4.63 1.71 17.37 3.74 0.0321a 47.35 15.97 0.0081a 28.53 4.43 0.0081a 
  3,4-Dihydroxyphenylvaleric acid 8.74 2.49 70.33 18.25 0.0081a 47.14 12.24 0.0161a 86.66 22.09 0.0081a 
  Sulf-3,4-dihydroxyphenylvaleric acid 28.02 11.34 530.70 160.71 0.0081a 1053.66 220.98 0.0081a 1061.01 403.49 0.0081a 
  Total 72.49 23.05 639.03 182.16 0.0081a 1250.23 223.86 0.0081a 1334.09 482.74 0.0081a 
Phenylpropionic acids            
  3-Hydroxyphenylpropionic acid 6638.51 2746.72 4097.84 597.18  14257.84 9274.35  8957.36 2307.88  
  4-Hydroxyphenylpropionic acid >60  >60   >60   >60   
  Gluc-3-  or-  4hydroxyphenylpropionic acid 21.34 12.93 13.93 6.64  17.10 2.09  28.36 11.52  
Dihydrocaffeic acid (3,4-
Dihydroxyphenylpropionic acid)  
3.65 1.60 10.49 2.65  56.85 45.95 0.0321a 20.82 5.86  
  Sulf-3,4-dihydrocaffeic acid 39.65 15.31 41.14 10.75  120.60 76.86  60.74 15.85  
  Total2 670.47 2751.81 4163.41 610.83  14452.40 9397.29  9067.28 2334.52  
 33 
Phenylacetic acids            
  3-Hydroxyphenylacetic acid 63.14 26.56 324.13 67.53 0.0081a 427.27 67.29 0.0081a 838.83 284.14 0.0321a 
  4-Hydroxyphenylacetic acid 60.97 23.56 532.53 142.90 0.0081a 1816.39 312.24 0.0081a 
0.0321b 
1859.17 585.26 0.0081a 
  3,4-Dihydroxyphenylacetic acid 0.86 0.36 3.09 0.61 0.0161a 10.27 5.04 0.0081a 16.65 4.87 0.0161a 
  Sulf-3,4-dihydroxyphenylacetic acid 7.79 4.41 8.91 1.48  8.41 1.90  14.19 4.19  
  Total   132.77 46.12 868.66 170.81 0.0081a 2262.34 292.60 0.0081a 
0.0161b 
2728.84 745.56 0.0081a 
Benzoic acids            
  4-Hydroxybenzoic acid 13.88 5.56 78.01 23.75 0.0081a 63.86 20.04 0.0321a 52.31 13.40  
  3,4-Dihydroxybenzoic acid 0.36 0.22 7.16 2.72 0.0161a 21.35 9.80 0.0081a 19.36 11.58 0.0081a 
   Gluc-3-hydroxybenzoic acid 0.24 0.13 1.04 0.34  2.73 1.17 0.0081a 1.77 0.50 0.0321a 
  Gluc-4-hydroxybenzoic acid 0.02 0.01 0.14 0.03 0.0321a 0.31 0.09 0.0081a 0.26 0.17 0.0321a 
  Sulf-3,4-dihydroxybenzoic acid 6.52 2.08 20.11 3.45 0.0081a 69.10 37.61 0.0081a 34.97 9.90 0.0321a 
  Sulf-vanillic-acid 327.72 64.53 681.32 200.67  459.50 78.29  1432.01 507.86  
  Total 348.74 60.23 787.78 228.73  616.85 129.27 0.0161a 1540.69 539.51  
Cinnamic acids            
  Caffeic acid 0.95 0.44 1.18 0.74  3.07 1.85  1.39 0.45  
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  m-Coumaric acid 116.69 54.97 102.91 29.16  247.53 30.90  140.64 47.78  
  p-Coumaric acid 24.03 8.90 20.41 10.93  32.90 9.37  46.87 31.48  
  Sulf-coumaric acid-1 n.d.  6.53 4.78 0.0081a 14.05 4.77 0.0081a 7.67 5.87 0.0081a 
  Sulf-coumaric acid-2 0.04 0.01 7.00 5.09 0.0321a 13.37 4.17 0.0081a 7.53 5.76 0.0081a 
  Ferulic acid 15.31 6.21 18.23 15.20  20.30 7.54  29.46 14.32  
  Total 157.02 65.75 156.26 65.01  331.22 44.11  235.56 101.24  
Glycinated benzoic acids            
  Hippuric acid 48.02 17.74 1385.71 396.40 0.0081a 2219.53 1311.56 0.0081a 1494.77 317.90 0.0081a 
  Hydroxyhippuric acid 0.29 0.26 14.31 5.03 0.0081a 16.99 3.57 0.0081a 18.23 5.35 0.0081a 
  Me-hippuric acid-1 0.15 0.15 67.03 54.54 0.0081a 94.37 35.88 0.0081a 73.06 57.30 0.0081a 
  Me-hippuric acid-2 2.91 1.22 5.49 4.84  14.05 7.41  16.62 13.76  
  Total 51.37 18.50 1472.53 443.46 0.0081a 2344.94 1313.91 0.0081a 1602.68 328.88 0.0081a 
 
n.d., non-detected; Gluc, glucuronide; Me, methyl; Sulf, sulfated  
Compounds detected in all the groups above the highest concentration of the calibration: Enterolactone, Sulf-Enterolactone and 4-Hydroxyphenylpropionic acid  
1 Values are mean + SEM , n=5 
2 Molinar-Toribio et al., in press. 
a differences with respect to STD group; b differences with respect to ω-3 group. Comparisons were performed using the Kruskal-Wallis and Mann-Whitney U tests; pairs 
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comparisons were performed between all the groups.
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Table 3. Microbial-derived proanthocyanidin metabolites in feces from rats fed a standard diet without supplementation (STD) or supplemented 
with ω-3 PUFAs (ω-3), grape seed extract (GSE) or ω-3 PUFAs and grape seed extract (ω-3 + GSE)1. Results expressed as µmol/ g dried feces, 
adjusted per kg feed intake/kg body weight, after quantification with structurally similar commercial standards (see Table S3). 
Metabolite STD2 ω-3 GSE2 ω-3 + GSE 
 Mean SEM Mean SEM P Mean SEM P Mean SEM P 
Lignans            
  Enterolactone > 60  > 60   > 60   > 60   
Phenylvaleric acids            
  3-Hydroxyphenylvaleric acid  3.14 1.47 78.48 36.55 0.0161a 
 
985.26 872.17 0.0081a 
 
975.65 485.91 0.0081a 
 
Phenylpropionic acids            
  3-Hydroxyphenylpropionic acid 45.05 3.84 35.68 23.50 0.0161a 
 
101.96 93.02 0.0081a 
 
12.60 0.00 0.0081a 
 
  4-Hydroxyphenylpropionic acid 10.91 2.77 381.06 242.99 0.0321a 
 
41.15 32.21  2033.79 1653.65 0.0321a 
 
  Total  55.96 41.61 416.73 246.22  143.10 90.51  2046.39 1653.65  
Benzoic acids            
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  4-hydroxybenzoic acid n.d.  0.15 0.10  1.06 0.75 0.0081a 
 
3.94 1.68 0.0081a 
 
  3,4-Dihydroxybenzoic acid n.d.  n.d.   0.22 0.16 0.0081a,b 
 
0.26 0.14 0.0321a, b 
 
  Total n.d.  0.15 0.10  1.27 0.91 0.0081a 
 
4.20 1.72 0.0081a 
 
Cinnamic acids            
  Caffeic acid 0.01 0.01 0.51 0.29 0.0081a 
 
0.53 0.41 0.0081a 
 
1.55 0.67 0.0081a 
 
  p-coumaric acid 0.04 0.02 1.66 1.02  2.72 2.06 0.0321a 
 
4.83 1.76 0.0321a 
 
  Total 0.05 0.03 2.16 1.31 0.0321a 
 
3.25 2.47 0.0321a 
 
6.38 2.41 0.0161a 
 
Glycinated benzoic acids            
  Hippuric acid 0.05 0.03 0.75 0.75  0.04 0.03  1.50 0.76  
  Me-hippuric acid-1 6.54 5.23 486.95 453.35  12279.53 11463.14  1023.35 584.48  
  Me-hippuric acid-2 n.d.  269.32 165.44 0.0081a 
 
6283.37 5735.59 0.0081a 
 




  Total   6.59 5.24 757.01 567.91  18562.94 17211.60 0.0081a 
 
1162.33 554.38 0.0081a 
 
n.d., non-detected; Gluc, glucuronide; Me, methyl; Sulf, sulfated  
1 Values are mean + SEM , n=5  
2 Molinar-Toribio et al., in press.       
a differences with respect to STD group; b differences with respect to ω-3 group. Comparisons were performed using the Kruskal-Wallis and Mann-Whitney U tests; pairs 
comparisons were performed between all the groups. 
